Aurinia Pharmaceuticals Inc
AUPH7.490USD
+0.010+0.13%
Cierre 07/02, 16:00（ET）Cotizaciones retrasadas 15 min
1.03BCap. mercado
25.89P/E TTM
Más Datos de Aurinia Pharmaceuticals Inc Compañía
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Información de la empresa
Símbolo de cotizaciónAUPH
Nombre de la empresaAurinia Pharmaceuticals Inc
Fecha de salida a bolsaJul 16, 2001
Fundada en2009
Director ejecutivoMr. Peter S. Greenleaf
Número de empleados130
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 16
Dirección#140, 14315 - 118 Avenue
CiudadEDMONTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísCanada
Código postalT5L 4S6
Teléfono12507442487
Sitio Webhttps://www.auriniapharma.com
Símbolo de cotizaciónAUPH
Fecha de salida a bolsaJul 16, 2001
Fundada en2009
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Craig Johnson
Mr. Craig Johnson
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Desglose de ingresos
Divisa: USDActualizado: hace 7 horas
Divisa: USDActualizado: hace 7 horas
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
Accionistas
Accionistas
Proporción
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
14.35%
Investment Advisor
12.78%
Investment Advisor/Hedge Fund
12.71%
Corporation
6.57%
Venture Capital
3.02%
Research Firm
2.96%
Individual Investor
2.80%
Pension Fund
0.52%
Bank and Trust
0.35%
Other
43.95%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
436
77.25M
57.17%
-345.00
2025Q1
457
75.49M
55.51%
-3.25M
2024Q4
454
71.04M
51.53%
-9.95M
2024Q3
449
70.86M
49.85%
-8.98M
2024Q2
452
69.33M
48.80%
-9.83M
2024Q1
446
69.12M
48.16%
-8.26M
2023Q4
460
67.04M
46.69%
-7.24M
2023Q3
469
63.17M
44.06%
-14.31M
2023Q2
493
65.34M
45.61%
-23.55M
2023Q1
499
65.33M
45.73%
-27.23M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Tang Capital Management, LLC
10.03M
7.42%
+1.60M
+18.98%
Mar 31, 2025
ILJIN SNT Co., Ltd.
8.88M
6.57%
+2.48M
+38.78%
Apr 12, 2025
BlackRock Institutional Trust Company, N.A.
7.47M
5.53%
-150.03K
-1.97%
Mar 31, 2025
Armistice Capital LLC
5.00M
3.7%
-1.40M
-21.88%
Mar 31, 2025
New Enterprise Associates (NEA)
3.97M
2.94%
--
--
Mar 31, 2025
State Street Global Advisors (US)
2.85M
2.11%
-66.87K
-2.29%
Mar 31, 2025
The Vanguard Group, Inc.
1.94M
1.44%
+241.86K
+14.20%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.74M
1.29%
+754.77K
+76.56%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.73M
1.28%
-30.09K
-1.71%
Mar 31, 2025
Arrowstreet Capital, Limited Partnership
1.64M
1.21%
+564.52K
+52.47%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: hace 19 horas
Actualizado: hace 19 horas
Nombre
Proporción
Virtus LifeSci Biotech Products ETF
1.48%
ALPS Medical Breakthroughs ETF
0.93%
Janus Henderson Small Cap Growth Alpha ETF
0.7%
SPDR S&P International Small Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.12%
Vanguard US Momentum Factor ETF
0.1%
iShares Biotechnology ETF
0.1%
Vanguard US Multifactor ETF
0.1%
Avantis US Small Cap Equity ETF
0.09%
Ver más
Virtus LifeSci Biotech Products ETF
Proporción1.48%
ALPS Medical Breakthroughs ETF
Proporción0.93%
Janus Henderson Small Cap Growth Alpha ETF
Proporción0.7%
SPDR S&P International Small Cap ETF
Proporción0.14%
Invesco Nasdaq Biotechnology ETF
Proporción0.12%
ProShares Ultra Nasdaq Biotechnology
Proporción0.12%
Vanguard US Momentum Factor ETF
Proporción0.1%
iShares Biotechnology ETF
Proporción0.1%
Vanguard US Multifactor ETF
Proporción0.1%
Avantis US Small Cap Equity ETF
Proporción0.09%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
